AstraZeneca COVID drug neutralises Omicron sub-variants in lab study
AstraZeneca said on Monday its antibody-based cocktail to prevent and treat COVID-19 retained neutralising activity against Omicron coronavirus variants, including the highly contagious BA.2 sub-variant, in an independent lab study.
www.reuters.com
Great news for the pharma company.